& Pipeline

Antibody and
CAR T-cell therapeutics

From our unique pool of antibodies, we select the most promising candidates, thereby concentrating on first-in-class antibodies, and develop them to antibody therapies and diagnostics, ADCs, and CAR T- and NK-cells.

Identification of cancer target proteins & development of novel antibodies

When it comes to new immunotherapeutic approaches, it’s all about suitable target molecules. Historically the target protein repertoire is limited by the fact that membrane proteins on cancer cells classically also exist on normal cells. Thus antibody-based therapies may also address normal cells, causing off-target effects and therapy failure.

Eximmium has set out to revolutionize cancer treatment by identifying completely new targets and simultaneously generating superior monoclonal antibodies. Currently, we focus on proteins which are located inside of normal cells whereas in cancer cells they become externalized to the surface. These proteins can be considered the holy grail for future immunotherapies of solid tumors as they are tumor-specific and druggable targets for antibodies and e.g. CAR-T cells.

EV engineering & analytics

Extracellular vesicles (EVs) are membrane-enclosed nanoparticles known to belong to the bodies inter-cellular communication systems. They contain genetic material and functional proteins and serve as conveyors of information.

EVs released from tumor cells represent the malignant phenotype intrinsic to the cancer cells reflected e.g. by the protein composition of the cell and EV surfaces equally. For this reason EVs represent promising tools for liquid biopsy and are currently under investigation in clinical diagnosis.

Eximmium has a long-standing experience how to isolate, characterize and modify EVs from different sources. Combining this knowledge with our proprietary antibody pool, we offer new opportunities for examining serum and plasma samples with regard for diagnostic approaches.

Eximmium provides

  • Customized standard EVs carrying one or more membrane proteins of interests

  • Suitable antibodies for the detection of EV-associated markers

  • EV analysis using different technologies